#Denmark #Roche Diagnostics #Nordic Bioscience #PRO-C3 #Herlev

Nordic Bioscience Unveils the PRO-C3 Test on Roche Diagnostics Cobas Analyzers

On May 8, 2025, Nordic Bioscience officially announced the launch of its groundbreaking PRO-C3 test, which will now be available on the Roche Diagnostics cobas e 801 platform. This advancement represents a significant step forward in assessing the severity of liver fibrosis, a condition responsible for one in every 25 deaths globally. The Elecsys® PRO-C3 assay, utilized in conjunction with the ADAPT formula—incorporating age, diabetic status, PRO-C3 levels, and platelet counts—offers a revolutionary approach to liver health evaluation.

Commitment to Precision Medicine

The Nordic PRO-C3 biomarker has already been validated in the CAP-CLIA certified laboratory in Denmark, showcasing Nordic Bioscience's dedication to enhancing patient care through precision medicine. The company ensures that its platform meets the stringent quality standards necessary for regulatory approval.

Over the past decade, Nordic Bioscience has established itself as a leader in this field, publishing over 250 scientific articles related to the PRO-C3 biomarker and its implications in fibrosis-related diseases. This robust body of research underscores the reliability and importance of the PRO-C3 test in clinical settings.

The First of Its Kind

The PRO-C3 is the premier biomarker for fibrosis developed by Nordic Bioscience to receive CE marking approval. Given that alterations in organ functionality—including liver health—account for 40% of deaths in the Western world, this test is crucial for quantifying those changes. It represents the cutting-edge of modern clinical chemistry and its integration into patient care workflows.

“We are thrilled to announce the launch of Elecsys PRO-C3, marking a milestone in our collaboration with Roche Diagnostics. Our technology is poised for global accessibility, fundamentally transforming the experience for patients at risk for liver disease,” stated Morten Karsdal, CEO of Nordic Bioscience.

About the PRO-C3 Test

The PRO-C3 test originated from Nordic Bioscience and was previously offered solely as a service through their Danish laboratory using the nordicPRO-C3™ test. The Elecsys PRO-C3 is developed as part of a licensing agreement between Nordic Bioscience and Roche Diagnostics, allowing it to reach a broader audience. For further scientific insights into the PRO-C3 test, interested parties are encouraged to visit the Nordic Bioscience website at nordicbioscience.com.

About Nordic Bioscience

Based in Herlev, Denmark, Nordic Bioscience specializes in biomarker innovations, leveraging unique neoepitope technology. By integrating biomarker development with preclinical and clinical research, Nordic Bioscience aims to create objective decision-making tools that facilitate the swift selection and development of compounds in clinical trials while enhancing diagnostic value for patients. More information can be found at nordicbioscience.com.

With the PRO-C3's introduction, Nordic Bioscience continues to pave the way in biomarker technology, delivering valuable tools for both clinicians and patients, ultimately aiming to reduce the global impact of liver disease.